X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Indian Stock Market News, Equity Market and Sensex Today in India | Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Engineering & banking revive markets
Wed, 5 Mar 01:30 pm

After slipping in red Indian share markets rebounded and are trading well above the dotted line in the post-noon trading session. Barring consumer durable and auto, all the sectoral indices are trading in the green with capital goods, banking and realty stocks being the biggest gainers.

BSE-Sensex is up 69 points and NSE-Nifty is trading 23 points up. BSE Mid Cap is trading 0.8% up and BSE Small Cap index is trading up by 0.3%. The rupee is trading at 61.8 to the US dollar.

Most of the engineering stocks are trading in the green with Bharat Bijlee and Alstom Projects being the biggest gainers. As per Indian Electrical and Electronics Manufacturers' Association (IEEMA), production of electrical equipment after registering a rise of 9.8% in 2QFY14 fell by 0.9% in 3QFY14. The fall has been on account of delays in project execution and non-adherence to payment schedules by distribution companies. This is likely to adversely impact the liquidity profile of electrical equipment manufacturers making it difficult for them to get bank credit. The cumulative growth in production of electrical equipment was merely 9% during 9mFY14.

Majority of the pharma stocks are trading in the green with Aurobindo Pharma and Elder Pharma being among major gainers whereas Panacea Biotech and Ipca Labs are a few stocks trading in the red. As per a leading financial daily, Dr. Reddy's Laboratories has launched moxifloxacin hydrochloride tablets in 400 mg strength in the US markets. Dr. Reddy's moxifloxacin hydrochloride drug is an equivalent generic version of Aktiengesellschaft's Avelox used for treating bacterial infections. According to IMS Health, Avelox sales in the US were around $195 m in 2013. Dr. Reddy's stock is trading marginally down.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

Read the latest Market Commentary

Equitymaster requests your view! Post a comment on "Engineering & banking revive markets". Click here!

  

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

S&P BSE HEALTHCARE


Feb 22, 2018 (Close)

MARKET STATS